Non-responders however, demonstrated less significant decreases in the tumor hemoglobin, relative to the pre-treatment value (76.7 ± 9.2% [HbO2]; 81.9 ± 9.4% [Hb]) and this was also correlated to a lesser change in the MBF and SI (+1.6 ± 1.4 dBr and +2.8 ± 1.6 dBr, respectively). This evidence concerns the gene GSTM1 and neoplasm.